Michael MS - Inotiv Chief Officer
| NOTV Stock | USD 3.66 0.12 3.39% |
Executive
Michael MS is Chief Officer of Inotiv Inc
| Age | 56 |
| Address | 2701 Kent Avenue, West Lafayette, IN, United States, 47906 |
| Phone | 765 463 4527 |
| Web | https://www.inotivco.com |
Inotiv Management Efficiency
The company has return on total asset (ROA) of (0.0292) % which means that it has lost $0.0292 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4315) %, meaning that it created substantial loss on money invested by shareholders. Inotiv's management efficiency ratios could be used to measure how well Inotiv manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to climb to -0.25 in 2024. Return On Capital Employed is likely to climb to -0.12 in 2024. At this time, Inotiv's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to climb to about 776.1 M in 2024, despite the fact that Return On Tangible Assets are likely to grow to (0.25).Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Jennifer McDonough | Krystal Biotech | N/A | |
| Kathryn Romano | Krystal Biotech | 42 | |
| James Reddoch | Royalty Pharma Plc | 54 | |
| Alexander Constan | Ikena Oncology | N/A | |
| Gopi Shanker | Beam Therapeutics | N/A | |
| Stephane Paquette | Krystal Biotech | N/A | |
| Candice Masse | Elevation Oncology | N/A | |
| Joan MBA | Verve Therapeutics | 55 | |
| Sandy Balkin | Royalty Pharma Plc | N/A | |
| Amy MD | Beam Therapeutics | 60 | |
| Snehal Patel | Sana Biotechnology | N/A | |
| Amy CFA | Caribou Biosciences | N/A | |
| Sara Klymkowsky | Royalty Pharma Plc | N/A | |
| David MS | Ikena Oncology | N/A | |
| Farah Anwar | Sana Biotechnology | N/A | |
| Richard Mulligan | Sana Biotechnology | 69 | |
| Kristin Stafford | Royalty Pharma Plc | 42 | |
| Biren Shah | Elevation Oncology | N/A | |
| John Cavan | Hepion Pharmaceuticals | 66 | |
| JD Esq | Caribou Biosciences | 69 | |
| Jennifer Robinson | Verve Therapeutics | N/A | |
Management Performance
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.0292 |
Inotiv Inc Leadership Team
Elected by the shareholders, the Inotiv's board of directors comprises two types of representatives: Inotiv inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Inotiv. The board's role is to monitor Inotiv's management team and ensure that shareholders' interests are well served. Inotiv's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Inotiv's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Adrian Hardy, Executive Development | ||
| Fernanda Beraldi, Gen Sec | ||
| Mo Dastagir, Chief Officer | ||
| Peter Kissinger, Chairman Founder | ||
| Kimberly Beaty, Director Marketing | ||
| William Pitchford, Chief Officer | ||
| Robert Leasure, CEO President | ||
| Brennan Freeman, Principal Finance | ||
| Andrea Castetter, Corporate Counsel | ||
| Michael MS, Chief Officer | ||
| Beth CPA, Senior CFO | ||
| Jeffrey Krupp, Chief Officer | ||
| DABT BSc, Group Assessment | ||
| Lizanne Muller, Group RMS | ||
| John DSA, Chief Assessment | ||
| DVM DiplomateACVP, Chief Director |
Inotiv Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Inotiv a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.0292 | ||||
| Profit Margin | (0.20) % | ||||
| Operating Margin | (0.17) % | ||||
| Current Valuation | 507.41 M | ||||
| Shares Outstanding | 26 M | ||||
| Shares Owned By Insiders | 13.47 % | ||||
| Shares Owned By Institutions | 13.92 % | ||||
| Number Of Shares Shorted | 1.47 M | ||||
| Price To Earning | 30.91 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Inotiv Stock Analysis
When running Inotiv's price analysis, check to measure Inotiv's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inotiv is operating at the current time. Most of Inotiv's value examination focuses on studying past and present price action to predict the probability of Inotiv's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inotiv's price. Additionally, you may evaluate how the addition of Inotiv to your portfolios can decrease your overall portfolio volatility.